Clear Scientific

Clear Scientific is a private, preclinical-stage biotech developing a platform of small-molecule sequestrants to rapidly remove harmful substances from the body. Its lead programs target overdoses from methamphetamine and fentanyl, aiming to provide rapid reversal via injection and reduce absorption via oral administration. The company is led by a seasoned executive team with deep experience in drug development, specialty chemicals, and defense technology, positioning it to address significant unmet needs in addiction and CNS disorders.

Platform of engineered small-molecule sequestrants that bind, inactivate, and clear specific harmful substances from the body via injection ('molecular dialysis') or oral administration (targeting gut-brain axis).

In overdose reversal, competition includes generic naloxone, its new formulations, and early-stage biotechs exploring monoclonal antibodies. For metabolic disorders, competitors include existing standard-of-care and other novel detoxification approaches. Clear Scientific's small-molecule approach aims for rapid action and oral bioavailability as potential differentiators.